🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. Vemurafenib

    Hoffmann-La Roche

    Malignant Melanoma

    phase 3 small molecule completed

    2 trials

  2. Venofer 200 MG Per 10 ML Injection

    Arrowhead Pharmaceuticals Ireland Limited

    Iron Deficiency Anemia of Pregnancy

    phase 3 small molecule active

    1 trial

  3. YM060

    Astellas Pharma Inc

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  4. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    B-cell Malignancies

    phase 3 small molecule active

    1 trial

  5. Zanubrutinib

    BeiGene

    B-cell Malignancies

    phase 3 small molecule active

    2 trials

  6. Zanubrutinib

    BEONE MEDICINES AUS PTY LTD

    B-cell malignancies

    phase 3 small molecule active

    1 trial

  7. didroxyprogesterone

    The First People's Hospital of Lianyungang

    Pregnancy Rate

    phase 3 small molecule active

    1 trial

  8. mRNA-4157, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    The participants must have a histologically confirmed diagnosis of resectable cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).

    phase 3 small molecule active

    1 trial

  9. recombinant human erythropoietin

    The First People's Hospital of Lianyungang

    Lymphoma

    phase 3 small molecule active

    1 trial

  10. recombinant human thrombopoietin

    The First People's Hospital of Lianyungang

    Immune Thrombocytopenia

    phase 3 small molecule active

    1 trial

  11. recombinant human thrombopoietin (rhTPO); dexamethasone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  12. recombinant human thrombopoietin (rhTPO); rituximab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule terminated

    1 trial

  13. recombinant interferon alfa

    United Therapeutics Europe Ltd

    Melanoma (Skin)

    phase 3 mab completed

    1 trial

  14. rhIDU (recombinant human-Alpha-L-Iduronidase)

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    phase 3 mab completed

    1 trial

  15. rituximab; recombinant human thrombopoietin (rhTPO)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Purpura

    phase 3 small molecule completed

    1 trial

  16. von Willebrand factor (Recombinant)

    Takeda

    Von Willebrand Disease

    phase 3 mab completed

    1 trial

  17. A randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study of brivekimig followed by a maintenance period in participants with moderate to severe hidradenitis suppurativa

    Sanofi-aventis Healthcare Pty Ltd

    Hidradenitis suppurativa

    phase 2 other active

    1 trial

  18. ADCETRIS 50 mg powder for concentrate for solution for infusion

    Takeda

    Hodgkin lymphoma (HL) - Hodgkin lymphoma (HL), a neoplasm of lymphoid tissue which is histopathologically defined by the presence of malignant Hodgkin Reed-Sternberg (HRS) cells in a background of inflammatory cells. The proposed pediatric study has been designed to evaluate brentuximab vedotin as a component of a multiagent frontline chemotherapy regimen in patients with advanced stage, newly diagnosed HL, here defined as Stage III and Stage IV and a ≥50 Lansky Play-Performance or Karnofsky Performance Status.

    phase 2 small molecule active

    1 trial

  19. AK104

    Akeso

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  20. AUTO1, MabThera 500 mg concentrate for solution for infusion, AUTO4, MabThera 100 mg concentrate for solution for infusion

    Autolus GmbH

    Potential malignancy in patients who received treatment with Autolus CAR T cell therapy.

    phase 2 small molecule active

    1 trial

  21. Abraxane 5 mg/ml powder for dispersion for infusion., PEMETREXED , GEN1042 DP, CARBOPLATIN , FLUOROURACIL , PACLITAXEL , PEMBROLIZUMAB, GEMCITABINE , CISPLATIN

    Genmab A/S

    Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

    phase 2 small molecule active

    1 trial

  22. Acasunlimab, Abraxane 5 mg/ml powder for dispersion for infusion., KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Accord 100 mg powder for concentrate for solution for infusion., Cisplatin 1mg/ml Injection BP, Carboplatin 10 mg/ml Intravenous Infusion, Pazenir 5 mg/ml powder for dispersion for infusion., Abraxane 5 mg/ml powder for dispersion for infusion.

    Genmab A/S

    Malignant solid tumors: endometrial carcinoma (EC), urothelial carcinoma (UC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (SCCHN), or cervical cancer.

    phase 2 small molecule active

    1 trial

  23. Aerosolized, Recombinant Alpha 1-Antitrypsin

    Takeda

    Alpha1-antitrypsin Deficiency

    phase 2 small molecule completed

    2 trials

  24. Allopregnanolone injection

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources